New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:44 EDTALNY, SNYAlnylam collaboration with Genzyme a 'major positive,' says Leerink
Leerink views Alnylam's (ALNY) expanded collaboration with Sanofi's (SNY) Genzyme as a major positive and thinks the stock could be sharply higher today. Further, the firm thinks Sirna could be worth more than the $175M deal price to Alnylam. Leerink keeps an Outperform rating on the stock.
News For ALNY;SNY From The Last 14 Days
Check below for free stories on ALNY;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:20 EDTALNYAlnylam to hold a roundtable
Subscribe for More Information
July 28, 2014
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
July 22, 2014
08:03 EDTALNYAlnylam receives USPTO Notice of Allowance for Manoharan 478 patent
Subscribe for More Information
07:22 EDTALNYAlnylam to hold a webinar
Subscribe for More Information
July 21, 2014
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 16, 2014
09:03 EDTSNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use